Premium
P1‐062: A PHASE II STUDY EVALUATING EFFICACY, SAFETY, AND TOLERABILITY OF ORAL BI 425809 IN PATIENTS WITH COGNITIVE IMPAIRMENT DUE TO ALZHEIMER'S DISEASE DEMENTIA
Author(s) -
Wunderlich Glen,
Jessen Frank,
Garcia Miguel,
Blahova Zuzana
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.06.087
Subject(s) - clinical dementia rating , tolerability , dementia , medicine , placebo , alzheimer's disease , population , clinical endpoint , neuropsychology , disease , clinical trial , adverse effect , psychology , cognition , oncology , psychiatry , pathology , environmental health , alternative medicine
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom